H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATNM stock, giving a Buy rating on March 27.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ promising future prospects. The company has demonstrated strong financial health with a cash reserve of $72.9 million, which is expected to sustain operations until mid-2027. This financial stability supports the company’s ability to continue advancing its pipeline without immediate funding concerns.
Furthermore, Actinium is actively progressing with multiple clinical trials, which include pivotal studies for their lead candidate, Actimab-A, in various combinations and indications. The initiation of these trials, along with expected data readouts in the near future, positions the company well for potential breakthroughs. Additionally, the company’s strategic collaborations and plans to present new data at significant conferences underscore its commitment to innovation and growth in the radiopharmaceutical space.
In another report released on March 27, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.
